Today’s post is by Marieke Dekker (Scientific Researcher at the Medicines Evaluation Board, CBG-MEB)

In Roadmap Work Package 6, regulatory and health technology assessment (HTA) involvement, we review past experiences of regulatory and HTA bodies with AD approved drugs. We evaluate studies and types of evidence used in both procedures and focus on similarities and differences in evidence requirements.

Read more>>